The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Open accessAbstract
Abstract Genetic and pharmacological studies of indoleamine 2,3-dioxygenase (IDO) have established this tryptophan catabolic enzyme as a central driver of malignant development and progression. IDO acts in tumor, stromal and immune cells to support pathogenic inflammatory processes that engender immune tolerance to tumor antigens. The multifaceted effects of IDO activation in cancer include the suppression of T and NK cells, the generation and activation of T regulatory cells and myeloid-derived suppressor cells, and the promotion of tumor angiogenesis. Mechanistic investigations have defined the aryl hydrocarbon receptor, the master metabolic regulator mTORC1 and the stress kinase Gcn2 as key effector signaling elements for IDO, which also exerts a non-catalytic role in TGF-β signaling. Small-molecule inhibitors of IDO exhibit anticancer activity and cooperate with immunotherapy, radiotherapy or chemotherapy to trigger rapid regression of aggressive tumors otherwise resistant to treatment. Notably, the dramatic antitumor activity of certain targeted therapeutics such as imatinib (Gleevec) in gastrointestinal stromal tumors has been traced in part to IDO downregulation. Further, antitumor responses to immune checkpoint inhibitors can be heightened safely by a clinical lead inhibitor of the IDO pathway that relieves IDO-mediated suppression of mTORC1 in T cells. In this personal perspective on IDO as a nodal mediator of pathogenic inflammation and immune escape in cancer, we provide a conceptual foundation for the clinical development of IDO inhibitors as a novel class of immunomodulators with broad application in the treatment of advanced human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,047
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
T cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Terness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 937
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
Tolerance, DCs and tryptophan: much ado about IDO
Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 735
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 703
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Mellor, A. L., & Munn, D. H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01520-0 · Cited by 648
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Self-citationSelective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
Self-citationAnczuków, O., Rosenberg, A. Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S. K., & Krainer, A. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2207 · Cited by 447
Sugimoto, H., Oda, S.-I., Otsuki, T., Hino, T., Yoshida, T., & Shiro, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508996103 · Cited by 441
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
The aryl hydrocarbon receptor: a perspective on potential roles in the immune system
Stevens, E. A., Mezrich, J. D., & Bradfield, C. A. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03054.x · Cited by 413
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Self-citationMetz, R., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 384
Self-citationIndoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Infectious tolerance via the consumption of essential amino acids and mTOR signaling
Cobbold, S. P., Adams, E., Farquhar, C. A., Nolan, K. F., Howie, D., Lui, K. O., Fairchild, P. J., Mellor, A. L., Ron, D., & Waldmann, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903919106 · Cited by 336
Creating immune privilege: active local suppression that benefits friends, but protects foes
Mellor, A. L., & Munn, D. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2233 · Cited by 327
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Self-citationIDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Self-citationReverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C., Belladonna, M. L., Ayroldi, E., Nocentini, G., et al. (2007) · Nature Medicine · doi:10.1038/nm1563 · Cited by 318
Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 304
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., & Hayaishi, O. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.129 · Cited by 292
Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5601 · Cited by 290
Baban, B., Chandler, P., McCool, D., Marshall, B., Munn, D. H., & Mellor, A. L. (2004) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2003.11.003 · Cited by 274
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Self-citationThe ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243
Koblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0628 · Cited by 242
Muller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
Self-citationGolan-Gerstl, R., Cohen, M., Shilo, A., Suh, S.-S., Bakàcs, A., Coppola, L., & Karni, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4410 · Cited by 232
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
McGaha, T. L., Huang, L., Lemos, H., Metz, R., Mautino, M., Prendergast, G. C., & Mellor, A. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01149.x · Cited by 197
Self-citationGe, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U., & Prendergast, G. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9689 · Cited by 195
Self-citationMetz, R., Smith, C., DuHadaway, J. B., Chandler, P., Baban, B., Merlo, L. M. F., Pigott, E., Keough, M. P., Rust, S., Mellor, A. L., et al. (2014) · International Immunology · doi:10.1093/intimm/dxt073 · Cited by 190
Self-citationIndoleamine 2,3‐dioxygenase: From catalyst to signaling function
Fallarino, F., Grohmann, U., & Puccetti, P. (2012) · European Journal of Immunology · doi:10.1002/eji.201242572 · Cited by 182
Boyland, E., & Williams, D. C. (1956) · Biochemical Journal · doi:10.1042/bj0640578 · Cited by 180
Belladonna, M. L., Grohmann, U., Guidetti, P., Volpi, C., Bianchi, R., Fioretti, M. C., Schwarcz, R., Fallarino, F., & Puccetti, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.130 · Cited by 179
Cutting Edge: Autocrine TGF-β Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells
Belladonna, M. L., Volpi, C., Bianchi, R., Vacca, C., Orabona, C., Pallotta, M. T., Boon, L., Gizzi, S., Fioretti, M. C., Grohmann, U., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5194 · Cited by 164
The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells
Chuang, H., Lan, J. L., Chen, D. Y., Yang, C. Y., Chen, Y., Li, J.-P., Huang, C., Liu, P. E., Wang, X., & Tan, T. (2011) · Nature Immunology · doi:10.1038/ni.2121 · Cited by 153
Radpour, R., Barekati, Z., Kohler, C., Lv, Q., Bürki, N., Diesch, C., Bitzer, J., Zheng, H. Y., Schmid, S. M., & Zhong, X. Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016080 · Cited by 146
TGF-β and kynurenines as the key to infectious tolerance
Belladonna, M. L., Orabona, C., Grohmann, U., & Puccetti, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.006 · Cited by 134
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
Basu, G. D., Tinder, T. L., Bradley, J. M., Tu, T., Hattrup, C. L., Pockaj, B. A., & Mukherjee, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2391 · Cited by 133
Iversen, T. Z., Engell-Noerregaard, L., Ellebæk, E., Andersen, R. S., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1560 · Cited by 132
Pineda‐Lucena, A., Ho, C. S. W., Mao, D. Y. L., Sheng, Y., Laister, R. C., Muhandiram, R., Lü, Y., Seet, B. T., Katz, S., Szyperski, T., et al. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.046 · Cited by 128
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Sørensen, R. B., Hadrup, S. R., Svane, I. M., Hjortsø, M. C., Straten, P. T., & Andersen, M. H. (2010) · Blood · doi:10.1182/blood-2010-06-288498 · Cited by 127
Tryptophan degradation increases with stage in patients with rheumatoid arthritis
Schroecksnadel, K., Winkler, C., Duftner, C., Wirleitner, B., Schirmer, M., & Fuchs, D. (2005) · Clinical Rheumatology · doi:10.1007/s10067-005-0056-6 · Cited by 120
Fallarino, F., Bianchi, R., Orabona, C., Vacca, C., Belladonna, M. L., Fioretti, M. C., SERREZE, D. V., Grohmann, U., & Puccetti, P. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040942 · Cited by 120
Willimsky, G., Czéh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., & Blankenstein, T. J. F. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072016 · Cited by 120
Marrying Immunotherapy with Chemotherapy: Why Say IDO?
Muller, A. J., & Prendergast, G. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2213 · Cited by 117
Self-citationThe Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity
Scott, G. N., DuHadaway, J. B., Pigott, E., Ridge, N. A., Prendergast, G. C., Muller, A. J., & Mandik‐Nayak, L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804328 · Cited by 116
Self-citationMerlo, L. M. F., Pigott, E., DuHadaway, J., Grabler, S., Metz, R., Prendergast, G., & Mandik-Nayak, L. (2014) · Journal of Immunology · doi:10.4049/jimmunol.1303012 · Cited by 110
Self-citationCancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now
Prendergast, G. C., & Jaffee, E. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4626 · Cited by 108
Self-citationPrendergast, G. C., Chang, M. Y., Mandik‐Nayak, L., Metz, R. A., & Muller, A. J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795656072 · Cited by 98
Self-citationRadpour, R., Kohler, C., Haghighi, M. M., Fan, A. X., Holzgreve, W., & Zhong, X. (2009) · Oncogene · doi:10.1038/onc.2009.149 · Cited by 97
Hu, H.-M., Tian, Q., Baer, M., Spooner, C. J., Williams, S. C., Johnson, P. F., & Schwartz, R. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910269199 · Cited by 93
Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Liu, X., Newton, R., Friedman, S., & Scherle, P. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192374 · Cited by 92
mTOR signalling and metabolic regulation of T cell differentiation
Peter, C., Waldmann, H., & Cobbold, S. P. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.08.010 · Cited by 88
Orabona, C., Belladonna, M. L., Vacca, C., Bianchi, R., Fallarino, F., Volpi, C., Gizzi, S., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6582 · Cited by 88
On watching the watchers: IDO and type I/II IFN
Puccetti, P. (2007) · European Journal of Immunology · doi:10.1002/eji.200737184 · Cited by 83
Yuan, W., Collado-Hidalgo, A., Yufit, T., Taylor, M. W., & Varga, J. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199810)177:1<174::aid-jcp18>3.0.co;2-d · Cited by 83
Lee, S. Y., Choi, H. K., Lee, K. J., Jung, J. Y., Hur, G. Y., Jung, K. H., Kim, J. H., Shin, C., Shim, J. J., In, K. H., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818ac2f7 · Cited by 81
Towards a Genetic Definition of Cancer-Associated Inflammation
Prendergast, G. C., Metz, R. A., & Muller, A. J. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091173 · Cited by 76
Self-citationPertovaara, M., Hasan, T., Raitala, A., Oja, S. S., Yli-Kerttula, U. I., Korpela, M. M., & Hurme, M. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03480.x · Cited by 74
Qian, F., Liao, J., Villella, J., Edwards, R. P., Kaliński, P., Lele, S., Shrikant, P. A., & Odunsi, K. O. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1265-x · Cited by 70
The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
Sørensen, R. B., Berge-Hansen, L., Junker, N., Hansen, C. A., Hadrup, S. R., Schumacher, T. N., Svane, I. M., Becker, J. C., Straten, P. T., & Andersen, M. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006910 · Cited by 69
BAR the door: Cancer suppression by amphiphysin-like genes
Prendergast, G. C., Muller, A. J., Ramalingam, A., & Chang, M. Y. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.09.001 · Cited by 68
Self-citationTumor suppressor TSC1 is critical for T-cell anergy
Xie, D., Wu, J., Lou, Y., & Zhong, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119744109 · Cited by 68
Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P. J., Metz, R. A., & Prendergast, G. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3613 · Cited by 65
Self-citationYuasa, H. J., Ball, H. J., Austin, C., & Hunt, N. H. (2010) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2010.04.006 · Cited by 58
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
Muller, A. J., DuHadaway, J. B., Chang, M. Y., Ramalingam, A., Sutanto‐Ward, E., Boulden, J., Soler, A. P., Mandik‐Nayak, L., Gilmour, S. K., & Prendergast, G. C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0891-4 · Cited by 57
Self-citationSpontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
Sørensen, R. B., Køllgaard, T., Andersen, R. S., van den Berg, J. H., Svane, I. M., Straten, P. T., & Andersen, M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3403 · Cited by 53
Levina, V. V., Su, Y., & Gorelik, E. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/173029 · Cited by 51
Chang, M. Y., Smith, C. B., DuHadaway, J. B., Pyle, J. R., Boulden, J., Soler, A. P., Muller, A. J., Laury‐Kleintop, L. D., & Prendergast, G. C. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.12.18142 · Cited by 48
Self-citationKita, H., Shiraishi, Y., Watanabe, K., Suda, K., Ohtsuka, K., Koshiishi, Y., & Goya, T. (2011) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.10.01627 · Cited by 38
Initiation of an Autoimmune Response: Insights from a Transgenic Model of Rheumatoid Arthritis
Mandik‐Nayak, L., & Allen, P. M. (2005) · Immunologic Research · doi:10.1385/ir:32:1-3:005 · Cited by 37
Self-citationRobson, W. L. M. (1928) · Biochemical Journal · doi:10.1042/bj0221157 · Cited by 29
Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
McKenna, E. S., Tamayo, P., Cho, Y., Tillman, E. J., Mora‐Blanco, E. L., Sansam, C. G., Koellhoffer, E. C., Pomeroy, S. L., & Roberts, C. W. M. (2012) · Cell Cycle · doi:10.4161/cc.20280 · Cited by 29
Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer
Kuznetsova, E., Kekeeva, T. V., Ларин, С. С., Zemlyakova, V. V., Khomyakova, A. V., Бабенко, О. В., Nemtsova, M. V., Zaletaev, D. V., & Strelnikov, V. V. (2007) · Journal of Carcinogenesis · doi:10.1186/1477-3163-6-9 · Cited by 27
Tumor-Induced Immune Suppression
Gabrilovich, D. I., & Hurwitz, A. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3 · Cited by 22
Malachowski, W. P., Metz, R., Prendergast, G. C., & Muller, A. J. (2005) · Drugs of the Future · doi:10.1358/dof.2005.030.09.918200 · Cited by 15
Self-citationPrendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.20909 · Cited by 14
Self-citationPrendergast, G. C., & Metz, R. A. (2012) · OncoImmunology · doi:10.4161/onci.21358 · Cited by 14
Self-citationIDO in Inflammatory Programming and Immune Suppression in Cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_11 · Cited by 8
Self-citation
Cited by
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Immunotherapy for glioma: Current management and future application
Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 746
Metadata
- Authors
- Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2014-04-08
- Volume
- 63
- Issue
- 7
- Pages
- 721-735
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2075094265
- Cited by
- 482
- References
- 102
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.